Detection and treatment of prostate cancer

A method of diagnosing prostate cancer in an individual, the method comprising the steps of:

• (a) contacting a sample from the individual with a binding moiety that binds specifically to a cancer-associated protein to produce a binding moiety-cancer-associated protein complex, the cancer-associated protein comprising an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:1;
• the sequence of SEQ ID NO:2;
• the sequence of SEQ ID NO:3;
• the sequence of SEQ ID NO:5;
• the sequence of SEQ ID NO:6;
• the sequence of SEQ ID NO:7;
• the sequence of SEQ ID NO:8;
• the sequence of SEQ ID NO:9;
• the sequence of SEQ ID NO:10;
• the sequence of SEQ ID NO:11, and a sequence comprising SEQ ID NO:4 and SEQ ID NO:12;
• and
• (b) detecting the complex, which if present is indicative of prostate cancer in the individual.

A composition comprising:

• an isolated polypeptide that
• (a) binds to an anion exchange resin comprising quarternary ammonium groups in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0,
• (b) elutes from the anion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, after the resin has been washed with a solution consisting essentially of 25 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, a solution consisting essentially of 50 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and a solution consisting essentially of 75 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and
• (c) comprises an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:1;
• the sequence of SEQ ID NO:2;
• the sequence of SEQ ID NO:3;
• the sequence of SEQ ID NO:5;
• the sequence of SEQ ID NO:6;
• the sequence of SEQ ID NO:7;
• the sequence of SEQ ID NO:8;
• the sequence of SEQ ID NO:9;
• the sequence of SEQ ID NO:10;
• the sequence of SEQ ID NO:11, and a sequence comprising SEQ ID NO:4 and SEQ ID NO:12.

A composition comprising:

• an isolated polypeptide that
• (a) binds to an anion exchange resin comprising quarternary ammonium groups in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0,
• (b) elutes from the anion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, after the resin has been washed with a solution consisting essentially of 25 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, a solution consisting essentially of 50 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and a solution consisting essentially of 75 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and
• (c) binds specifically to an anti-VDBP antibody.

A method of diagnosing cancer in an individual comprising:

• detecting in a sample isolated from the individual a polypeptide that
• (a) binds to an anion exchange resin comprising quarternary ammonium groups in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0,
• (b) elutes from the anion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, after the resin has been washed with a solution consisting essentially of 25 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, a solution consisting essentially of 50 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and a solution consisting essentially of 75 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and
• (c) comprises an amino acid sequence selected from the group consisting of the sequence of SEQ ID NO:1;
• the sequence of SEQ ID NO:2;
• the sequence of SEQ ID NO:3;
• the sequence of SEQ ID NO:5;
• the sequence of SEQ ID NO:6;
• the sequence of SEQ ID NO:7;
• the sequence of SEQ ID NO:8;
• the sequence of SEQ ID NO:9;
• the sequence of SEQ ID NO:10;
• the sequence of SEQ ID NO:11, and a sequence comprising SEQ ID NO:4 and SEQ ID NO:12, wherein presence of the polypeptide is indicative of cancer in the individual.

An isolated, prostate cancer-associated polypeptide, said polypeptide comprising the characteristics of:

• detectable at a higher concentration in serum of a human with prostate cancer than in serum of a human without prostate cancer;
• and
• (i) has a molecular weight of about 21 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion ion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0, and elutes from the ion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM to sodium phosphate, pH 7.0;
• (ii) has a molecular weight of about 23 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0, and elutes from the anion ion exchange resin in the presence of a second solution consisting essentially of 175 mM sodium chloride in 50 mM sodium phosphate, pH 7.0,
• (iii) has a molecular weight of about 25 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0, and elutes from the ion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0,
• (iv) has a molecular weight of about 26 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7, and elutes from the ion exchange resin in the presence of a second solution consisting essentially of 100 mM sodium chloride in 50 mM sodium phosphate, pH 7.0,
• (v) has a molecular weight of about 51 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0, elutes from an ion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0, and has an affinity for a derivatized chip surface bearing nickel ions,
• (vi) has a molecular weight of about 60 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface and weakly binds an anion exchange resin in the presence of a solution consisting essentially of 50 mM sodium phosphate, pH 7.0, or
• (vii) has a molecular weight of about 125 kD as measured by MALDI-TOF mass spectrometry using a derivatized chip surface, binds to an anion exchange resin in the presence of a first solution consisting essentially of 50 mM sodium phosphate, pH 7.0, and elutes from an ion exchange resin in the presence of a second solution consisting essentially of 125 mM sodium chloride in 50 mM sodium phosphate, pH 7.0.